Fakultni nemocnice Hradec Kralove

Hradec Králové, Hradec Králové 500 05

4 studies enrolling now · 11 studies all time

What they study most

Lymphoma, Mantle-Cell, Metastatic Castration-resistant Prostate Cancer, Metastatic Colorectal Cancer, Metastatic Non-small Cell Lung Cancer With MTAP Deletion, Migraine, Multiple Myeloma, Multiple Sclerosis Spasticity, Neoplasms, Pancreatic Ductal Adenocarcinoma, Relapsed or Refractory Multiple Myeloma (RRMM), Urothelial Carcinoma

Studies at this site

• A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion — Recruiting now
• A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) — Recruiting now
• A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer — Recruiting now
• A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity — Recruiting now
• A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer — Running, not enrolling
• A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine — Running, not enrolling
• Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 — Running, not enrolling
• A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer — Running, not enrolling
• A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) — Running, not enrolling
• Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) — Running, not enrolling
• Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant — Running, not enrolling